Jupiter Neurosciences Executes 1-for-75 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Jupiter Neurosciences' board approved a 1-for-75 reverse stock split effective August 6, 2026.
- The split reduces outstanding shares from ~57.8M to ~770K, aiming to meet Nasdaq's $1 minimum bid price requirement.
- Trading on a post-split basis begins August 7, 2026 under ticker JUNS with new CUSIP number 48208B302.
- Fractional shares will be paid out in cash based on the closing price prior to the split.
The big picture
Jupiter Neurosciences' reverse stock split is a defensive move to comply with Nasdaq's minimum bid price requirement, common among small-cap biotech firms facing liquidity challenges. The company joins peers in using capital structure adjustments to avoid delisting while advancing its clinical pipeline. Success hinges on maintaining compliance and demonstrating progress in its lead programs.
What we're watching
- Compliance Success
- Whether the reverse split will successfully maintain Nasdaq listing and avoid further delisting risks.
- Market Reaction
- How investors respond to the reduced share count and potential price increase post-split.
- Operational Focus
- The pace at which Jupiter advances its clinical-stage pipeline, particularly JOTROL for Parkinson's disease.